


Djibouti

Eastern Mediterranean Region



I. Epidemiological profile


Population (UN)	2015	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	0	-	Plasmodium species: <i>P. falciparum</i> (100%)0%
Low transmission (0-1 cases per 1000 population)	445,000	50	Major anopheles species: <i>An. gambiae</i> , <i>An. arabiensis</i>
Malaria-free (0 cases)	445,000	50	Reported confirmed cases (health facility): - Estimated cases: 5,600 [1,100 ; 18,000]
Total	890,000		Confirmed cases at community level: - Reported deaths: - Estimated deaths: <50

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2008	First-line treatment of unconfirmed malaria	AL+PQ	2014					
	ITNs/ LLINs distributed to all age groups	No	-	First-line treatment of <i>P. falciparum</i>	AL+PQ	2014					
IRS	IRS is recommended	Yes	2006	Treatment failure of <i>P. falciparum</i>	AS+AQ	2014					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS	-					
Larval control	Use of larval control recommended	Yes	2008	Treatment of <i>P. vivax</i>	CQ+PQ (14d)	-					
IPT	IPT used to prevent malaria during pregnancy	No	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2007	Type pf RDT used		-					
	Malaria diagnosis is free of charge in the public sector	Yes	2007								
Treatment	ACT is free of charge for all ages in public sector	Yes	2007	Therapeutic efficacy tests (clinical and parasitological failure, %)							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-	Medicine	Year	Min	Median	Max	Follow-up	No of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	2014								
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	2014								
	G6PD test is a requirement before treatment with primaquine	No	-								
	Directly observed treatment with primaquine is undertaken	No	-								
	System for monitoring adverse reactions to antimalarials exists	No	-								
Surveillance	ACD for case investigation (reactive)	No	-	Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)							
	ACD of febrile cases at community level (pro-active)	No	-	Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested		
	Mass screening is undertaken	No	-	2011	No	No		No	<i>An. gambiae</i> s.l.		
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	-	-								
Case reporting from private sector is mandatory	-	-									

III. Financing


Sources of financing




Government expenditure by intervention in 2015 2015

IV. Coverage

Coverage of ITN and IRS




Cases tested and treated in public sector




V. Impact


Cases treated



Test positivity



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths

